Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

While the cells seem to survive for months in mice, it’s not yet clear how long they will survive in humans, who live much longer lives, or whether they will affect the long-term function of the retina in other ways. For example, they might interfere with the interaction between the photoreceptors and the retinal pigment epithelium, says Reh.

Because the stem-cell treatment doesn’t replace lost cells, it most likely needs to be administered early in the course of a disease. “This would not be something for advanced macular degeneration, where the receptors are already damaged,” says Lund. “We would want to spot patients who are seriously as risk and hopefully slow or stop process of disease.” A number of genetic factors have been identified that boost risk for the disease, and genetic testing is available.

Taken together, retinitis pigmentosa and macular degeneration are the most common causes of blindness in people 40 and older. No treatments yet exist for the most common form of macular degeneration, which accounts for about 90 percent of cases. A number of novel therapies are under development, including drugs, cell transplants, and implanted devices. Advanced Cell Technology, based in Worcester, MA, uses human embryonic stem cells to grow retinal pigment epithelium, often the first cell type to die off in age-related macular degeneration and other eye diseases. The company filed for permission to begin clinical trials of the cells last November.

3 comments. Share your thoughts »

Credit: Trevor McGill

Tagged: Biomedicine, stem cells, blindness, vision, macular degeneration, retina, retinitis pigmentosa

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me